tagrisso
astrazeneca ab - osimertinib mesilate - rak, niedrobnokomórkowe płuca - inne leki przeciwnowotworowe, inhibitory białka kinazy - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.
artilla 0,075 mg + 0,02 mg tabletki drażowane
zentiva, k.s. - gestodenum + ethinylestradiolum - tabletki drażowane - 0,075 mg + 0,02 mg
rigevidon 0,03 mg + 0,15 mg tabletki powlekane
gedeon richter plc. - ethinylestradiolum + levonorgestrelum - tabletki powlekane - 0,03 mg + 0,15 mg
yasmin 0,03 mg + 3 mg tabletki powlekane
bayer ag - ethinylestradiolum + drospirenonum - tabletki powlekane - 0,03 mg + 3 mg
nuvaring (0,12 mg + 0,015 mg)/24 h system terapeutyczny dopochwowy
organon polska sp. z o.o. - etonogestrelum + ethinylestradiolum - system terapeutyczny dopochwowy - (0,12 mg + 0,015 mg)/24 h
midiana 3 mg + 0,03 mg tabletki powlekane
gedeon richter polska sp. z o.o. - drospirenonum + ethinylestradiolum - tabletki powlekane - 3 mg + 0,03 mg
madinette 0,03 mg + 2 mg tabletki powlekane
sun-farm sp. z o.o. - ethinylestradiolum + chlormadinoni acetas - tabletki powlekane - 0,03 mg + 2 mg
circlet (0,120 mg + 0,015 mg)/24 h system terapeutyczny dopochwowy
organon polska sp. z o.o. - etonogestrelum + ethinylestradiolum - system terapeutyczny dopochwowy - (0,120 mg + 0,015 mg)/24 h
daylette 3 mg + 0,02 mg tabletki powlekane
gedeon richter plc. - drospirenonum + ethinylestradiolum - tabletki powlekane - 3 mg + 0,02 mg
teenia 3 mg + 0,02 mg tabletki powlekane
gedeon richter polska sp. z o.o. - drospirenonum + ethinylestradiolum - tabletki powlekane - 3 mg + 0,02 mg